Dientamoeba fragilis

From WikiMD's WELLNESSPEDIA

Dientamoeba fragilis is a species of single-celled amoeba that is commonly associated with gastrointestinal illness. Despite its classification as an amoeba, it does not possess the typical morphological characteristics of other amoebae, such as pseudopodia for movement.

Taxonomy[edit]

Dientamoeba fragilis belongs to the kingdom Protista, phylum Amoebozoa, and class Archamoebae. It is the only species in the genus Dientamoeba.

Morphology[edit]

The morphology of D. fragilis is unique among amoebae. It lacks the pseudopodia typically used for movement and instead has a more passive mode of locomotion. The organism is binucleated, meaning it has two nuclei, and it reproduces through binary fission.

Pathogenicity[edit]

D. fragilis is a common cause of gastroenteritis, with symptoms including abdominal pain, diarrhea, and weight loss. However, many infected individuals are asymptomatic. The mechanism of pathogenicity is not well understood, but it is thought to involve damage to the intestinal epithelium.

Diagnosis and treatment[edit]

Diagnosis of D. fragilis infection is typically made through microscopic examination of stool samples. Treatment usually involves the use of antiprotozoal medications, such as metronidazole.

Epidemiology[edit]

D. fragilis is found worldwide, but is more common in developing countries. It is transmitted through the fecal-oral route, often via contaminated food or water.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.